Daily Stock Analysis, IPXL, Impax Laboratories Inc, priceseries

Impax Laboratories Inc. Daily Stock Analysis
Stock Information
Open
18.20
Close
18.30
High
18.95
Low
17.40
Previous Close
18.30
Daily Price Gain
0.00
YTD High
21.75
YTD High Date
Jan 26, 2018
YTD Low
16.57
YTD Low Date
Jan 2, 2018
YTD Price Change
0.70
YTD Gain
3.98%
52 Week High
25.70
52 Week High Date
Sep 21, 2017
52 Week Low
13.25
52 Week Low Date
Jun 15, 2017
52 Week Price Change
2.60
52 Week Gain
16.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 8. 2017
13.35
Feb 22. 2017
14.23
9 Trading Days
6.58%
Link
LONG
May 9. 2017
14.20
May 18. 2017
15.37
7 Trading Days
8.27%
Link
LONG
Jan 11. 2018
18.50
Jan 30. 2018
20.07
12 Trading Days
8.47%
Link
Company Information
Stock Symbol
IPXL
Exchange
NasdaqGS
Company URL
http://www.impaxlabs.com
Company Phone
510-240-6000
CEO
Paul M. Bisaro
Headquarters
California
Business Address
30831 HUNTWOOD AVENUE, HAYWARD, CA 94544
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001003642
About

Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture, and marketing of controlled-release and niche generics. It operates through the Impax Generics and Impax Specialty Pharma segments. The Impax Generics segment concentrates on the development manufacture, sale and distribution of generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Impax Specialty Pharma segment engages in the development of proprietary brand pharmaceutical products. The company was founded on December 14, 1999 and is headquartered in Hayward, CA.

Description

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment focuses on the development, sale, and distribution through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.